News | August 10, 2023
Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The product is being launched in August 2023
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The company has reported total income of Rs. 1248.51 crores during the period ended June 30, 2023
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
